115 related articles for article (PubMed ID: 31738155)
1. Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia.
Ziemba B; Sikorska H; Jander M; Kuncman W; Danilewicz M; Appelhans D; Bryszewska M; Borowiec M; Franiak-Pietryga I
Anticancer Agents Med Chem; 2020; 20(3):325-334. PubMed ID: 31738155
[TBL] [Abstract][Full Text] [Related]
2. Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL.
Franiak-Pietryga I; Ziemba B; Sikorska H; Jander M; Kuncman W; Danilewicz M; Appelhans D; Lewkowicz P; Ostrowska K; Bryszewska M; Borowiec M
Toxicol Appl Pharmacol; 2020 Sep; 403():115139. PubMed ID: 32687837
[TBL] [Abstract][Full Text] [Related]
3. Glycodendrimer PPI as a Potential Drug in Chronic Lymphocytic Leukaemia. The Influence of Glycodendrimer on Apoptosis in In Vitro B-CLL Cells Defined by Microarrays.
Franiak-Pietryga I; Ziółkowska E; Ziemba B; Appelhans D; Maciejewski H; Voit B; Kaczmarek A; Robak T; Klajnert-Maculewicz B; Cebula-Obrzut B; Smolewski P; Borowiec M; Bryszewska M
Anticancer Agents Med Chem; 2017; 17(1):102-114. PubMed ID: 27349446
[TBL] [Abstract][Full Text] [Related]
4. The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPI.
Franiak-Pietryga I; Ziółkowska E; Ziemba B; Appelhans D; Voit B; Szewczyk M; Góra-Tybor J; Robak T; Klajnert B; Bryszewska M
Mol Pharm; 2013 Jun; 10(6):2490-501. PubMed ID: 23641871
[TBL] [Abstract][Full Text] [Related]
5. Dendrimer-based nanoparticles for potential personalized therapy in chronic lymphocytic leukemia: Targeting the BCR-signaling pathway.
Franiak-Pietryga I; Maciejewski H; Ostrowska K; Appelhans D; Voit B; Misiewicz M; Kowalczyk P; Bryszewska M; Borowiec M
Int J Biol Macromol; 2016 Jul; 88():156-61. PubMed ID: 26987432
[TBL] [Abstract][Full Text] [Related]
6. PPI-G4 Glycodendrimers Upregulate TRAIL-Induced Apoptosis in Chronic Lymphocytic Leukemia Cells.
Franiak-Pietryga I; Ostrowska K; Maciejewski H; Appelhans D; Misiewicz M; Ziemba B; Bednarek M; Bryszewska M; Borowiec M
Macromol Biosci; 2017 May; 17(5):. PubMed ID: 27996200
[TBL] [Abstract][Full Text] [Related]
7. Affecting NF-κB cell signaling pathway in chronic lymphocytic leukemia by dendrimers-based nanoparticles.
Franiak-Pietryga I; Ostrowska K; Maciejewski H; Ziemba B; Appelhans D; Voit B; Jander M; Treliński J; Bryszewska M; Borowiec M
Toxicol Appl Pharmacol; 2018 Oct; 357():33-38. PubMed ID: 30125597
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: considering their contrary potential as biocompatible entity and drug molecule in cancer.
Ziemba B; Franiak-Pietryga I; Pion M; Appelhans D; Muñoz-Fernández MÁ; Voit B; Bryszewska M; Klajnert-Maculewicz B
Int J Pharm; 2014 Jan; 461(1-2):391-402. PubMed ID: 24361266
[TBL] [Abstract][Full Text] [Related]
9. Blockage of Wnt/β-Catenin Signaling by Nanoparticles Reduces Survival and Proliferation of CLL Cells In Vitro-Preliminary Study.
Franiak-Pietryga I; Maciejewski H; Ziemba B; Appelhans D; Voit B; Robak T; Jander M; Treliński J; Bryszewska M; Borowiec M
Macromol Biosci; 2017 Nov; 17(11):. PubMed ID: 28762636
[TBL] [Abstract][Full Text] [Related]
10. Poly(propylene imine) dendrimers modified with maltose or maltotriose protect phosphorothioate oligodeoxynucleotides against nuclease activity.
Drzewińska J; Appelhans D; Voit B; Bryszewska M; Klajnert B
Biochem Biophys Res Commun; 2012 Oct; 427(1):197-201. PubMed ID: 22995301
[TBL] [Abstract][Full Text] [Related]
11. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K
Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551
[TBL] [Abstract][Full Text] [Related]
12. Interactions of Nitroxide-Conjugated and Non-Conjugated Glycodendrimers with Normal and Cancer Cells and Biocompatibility Studies.
Andreozzi E; Antonelli A; Cangiotti M; Canonico B; Sfara C; Pianetti A; Bruscolini F; Sahre K; Appelhans D; Papa S; Ottaviani MF
Bioconjug Chem; 2017 Feb; 28(2):524-538. PubMed ID: 28068077
[TBL] [Abstract][Full Text] [Related]
13. Effect of poly(propylene imine) glycodendrimers on β-amyloid aggregation in vitro and in APP/PS1 transgenic mice, as a model of brain amyloid deposition and Alzheimer's disease.
Klementieva O; Aso E; Filippini D; Benseny-Cases N; Carmona M; Juvés S; Appelhans D; Cladera J; Ferrer I
Biomacromolecules; 2013 Oct; 14(10):3570-80. PubMed ID: 24004423
[TBL] [Abstract][Full Text] [Related]
14. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
Buchner M; Brantner P; Stickel N; Prinz G; Burger M; Bär C; Dierks C; Pfeifer D; Ott A; Mertelsmann R; Gribben JG; Veelken H; Zirlik K
Br J Haematol; 2010 Oct; 151(2):167-78. PubMed ID: 20738306
[TBL] [Abstract][Full Text] [Related]
15. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
16. Influence of surface groups on poly(propylene imine) dendrimers antiprion activity.
McCarthy JM; Rasines Moreno B; Filippini D; Komber H; Maly M; Cernescu M; Brutschy B; Appelhans D; Rogers MS
Biomacromolecules; 2013 Jan; 14(1):27-37. PubMed ID: 23234313
[TBL] [Abstract][Full Text] [Related]
17. Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance.
Szulc A; Pulaski L; Appelhans D; Voit B; Klajnert-Maculewicz B
Int J Pharm; 2016 Nov; 513(1-2):572-583. PubMed ID: 27667754
[TBL] [Abstract][Full Text] [Related]
18. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Robak T
Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
[TBL] [Abstract][Full Text] [Related]
19. Advances in chronic lymphocytic leukemia pharmacotherapy.
Gomes LC; Ferrão ALM; Evangelista FCG; de Almeida TD; Barbosa RC; Carvalho MDG; de Paula Sabino A
Biomed Pharmacother; 2018 Jan; 97():349-358. PubMed ID: 29091884
[TBL] [Abstract][Full Text] [Related]
20. Stability of dendriplexes formed by anti-HIV genetic material and poly(propylene imine) dendrimers in the presence of glucosaminoglycans.
Szewczyk M; Drzewinska J; Dzmitruk V; Shcharbin D; Klajnert B; Appelhans D; Bryszewska M
J Phys Chem B; 2012 Dec; 116(50):14525-32. PubMed ID: 23199071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
